Feb 27, 2019
Perrigo Company plc Reports Fourth Quarter And Full-Year 2018 Financial Results
Feb 25, 2019
Perrigo Receives Leave To Judicially Review Irish Revenue Tax Assessment
Feb 14, 2019
Perrigo Announces Quarterly Dividend
Feb 13, 2019
Perrigo Announces Patent Litigation Settlement for the Generic Version of Jublia® Topical Solution 10%
Feb 13, 2019
Perrigo Company plc To Release Fourth Quarter And Calendar Year 2018 Results On February 27, 2019
Feb 06, 2019
Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5%
Jan 29, 2019
Perrigo To Receive Milestone Payment Of $250 Million From RPI Finance Trust
Jan 14, 2019
Perrigo Appoints James Dillard To Role Of Chief Scientific Officer
Jan 07, 2019
RM LAW Announces Class Action Lawsuit Against Perrigo Company plc
Dec 20, 2018
Perrigo To Present At The J.P. Morgan Global Healthcare Conference
Dec 10, 2018
Perrigo Announces the Launch of an AB Rated Generic Version of Topicort® Topical Spray 0.25%
Nov 28, 2018
Perrigo Announces Patent Litigation Settlement For The Generic Version Of Sernivo® Spray, 0.05%
Nov 27, 2018
Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%
Nov 26, 2018
Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate® Lotion 0.05%
Nov 08, 2018
Perrigo Company plc Reports Third Quarter 2018 Financial Results
Oct 31, 2018
Perrigo Announces Quarterly Dividend
Oct 29, 2018
Perrigo Confirms Patent Challenge For Generic Version Of Kerydin®
Oct 26, 2018
Perrigo Confirms Patent Challenge For Generic Version Of Narcan®
Oct 25, 2018
Perrigo To Release Third Quarter Calendar Year 2018 Financial Results On November 8, 2018
Oct 15, 2018
Perrigo Announces The Launch Of An AB Rated Generic Version Of Androgel® Topical Gel, 1.62%